Cross-Sectional Epidemiological Analysis of the Nagahama Study for Correlates of Overactive Bladder: Genetic and Environmental Considerations

Funada, Satoshi; Kawaguchi, Takahisa; Terada, Naoki; Negoro, Hiromitsu; Tabara, Yasuharu; Kosugi, Shinji; Yamada, Ryo; Nakayama, Takeo; Akamatsu, Shusuke; Yoshimura, Koji; Matsuda, Fumihiko; Ogawa, Osamu

doi:10.1016/j.juro.2017.09.146

Cited by 22 publications

(37 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Overactive bladder (OAB) is defined as “urgency, with or without urgency incontinence, usually with frequency and nocturia.” [ 1 ] The prevalence of OAB is estimated to range between 10 and 20%, and increases with age [ 2 – 4 ]. OAB has a negative impact on lives.…”

Section: Introductionmentioning

confidence: 99%

Cognitive behavioral therapy for overactive bladder in women: study protocol for a randomized controlled trial

et al. 2020

Self Cite

View full text Add to dashboard Cite

Background Overactive bladder (OAB) symptoms affect daily life by decreasing health-related quality of life (HRQol). However, there remain no very effective treatment for OAB. Pharmacotherapy is one of the best treatments, but it is not always efficient and may incur adverse events. Although behavioral therapy is another effective treatment, there are very few structured treatment manuals on how to prescribe behavioral therapy to treat OAB for whom. Cognitive behavioral therapy (CBT) is a psychotherapy consisting of structured sessions to solve problems with the collaborative empiricism between therapists and patients. OAB symptoms are supposed to worsen with cognitive distortion, and CBT is expected to be effective in treating OAB by modifying such cognitive processes. In this trial, we will evaluate the efficacy of CBT for OAB. Methods A randomized, controlled, open-label, multicenter parallel-group superiority trial will be conducted. Participants with moderate to severe OAB symptoms with or without pharmacotherapy will be recruited and will be randomly allocated 1:1 to two different groups by minimization (age, baseline OAB severity, treatment status, types of intervention, and treating institutions). The intervention group will be prescribed an individual CBT program covering six techniques in 4 sessions (30 min each), with or without pharmacotherapy. The primary outcome is the change scores in an OAB-questionnaire (OAB-q) from baseline to the end of the trial (week 13). Secondary outcomes will include other patient reported outcome measures and the frequency volume chart. All analyses will be conducted on an intention-to-treat principle. Discussion This trial will determine the efficacy of CBT to treat OAB using a rigorous methodology. The effectiveness of CBT with a structured manual may not only lead to a new treatment option for patients suffering from OAB symptoms, but may also reduce the social burden by OAB. Trial registration UMIN-CTR Clinical Trial, CTR-UMIN000038513 . Registered on November 7, 2019.

show abstract

Section: Introductionmentioning

confidence: 99%

Cognitive behavioral therapy for overactive bladder in women: study protocol for a randomized controlled trial

et al. 2020

Self Cite

View full text Add to dashboard Cite

show abstract

“…1,2 OAB is a prevalent condition, and two epidemiological studies have estimated that 12% of the Japanese population exhibit OAB symptoms. 3,4 In both of these surveys, a slightly higher prevalence was noted for men compared with women. Patients with severe benign prostatic hyperplasia (BPH) typically experience higher levels of pain, more anxiety, and greater negative effects on their usual activities than patients with milder symptoms.…”

Section: Introductionmentioning

confidence: 91%

“…The occurrence of overactive bladder (OAB) syndrome can have a substantial impact on patients' quality of life (QoL), including affecting work productivity, anxiety, and increased healthcare usage 1,2 . OAB is a prevalent condition, and two epidemiological studies have estimated that 12% of the Japanese population exhibit OAB symptoms 3,4 . In both of these surveys, a slightly higher prevalence was noted for men compared with women.…”

Section: Introductionmentioning

confidence: 99%

Safety and effectiveness of mirabegron in male patients with overactive bladder with or without benign prostatic hyperplasia: A Japanese post‐marketing study

Takahashi

Kato

Tabuchi

et al. 2020

LUTS

View full text Add to dashboard Cite

Objectives: The aim of this post hoc analysis from the Japanese mirabegron surveillance program was to investigate the safety and effectiveness of mirabegron in male patients with overactive bladder (OAB) symptoms with/without concomitant benign prostatic hyperplasia (BPH). Methods: This 12-week study included patients who were starting mirabegron treatment for the OAB symptoms of urinary urgency, daytime frequency, and urgency urinary incontinence. Patients were stratified according to BPH diagnosis, and patients with BPH were stratified into those who did/did not receive BPH-specific treatment. Assessments included adverse drug reactions (ADRs), residual urine volume evaluations, and total Overactive Bladder Symptom Score (OABSS) and International Prostate Symptom Score-Quality of Life (IPSS-QoL) measurements. Results: Of 4540 male patients, 3176 (70.0%) had been diagnosed with BPH. Mean age was slightly higher in patients with BPH (74.7 ± 8.41 years) versus patients without BPH (71.0 ± 12.13 years). Overall, 66/1364 (4.84%), 170/2588 (6.57%), and 35/569 (6.15%) patients without BPH, with BPH + treatment, and with BPH + no treatment, respectively, experienced ≥1 ADR. No patients without BPH and 21/3176 (0.66%) patients with BPH experienced a urinary retention ADR. No significant changes from baseline to week 12 in residual volume were noted. Mirabegron was judged to be an effective treatment for 990/1296 (76.4%) patients without BPH, 1935/2491 (77.7%) patients with BPH + treatment, and 421/538 (78.3%) patients with BPH + no treatment. Significant decreases in total OABSS and IPSS-QoL were observed for all groups. Conclusions: Mirabegron was a well-tolerated and effective treatment for patients with OAB symptoms with or without BPH in this post-marketing study.

show abstract

“…Some 546 million individuals worldwide were expected to be affected by OAB in 2018 [3], with the overall prevalence increasing with advancing age and highest rates reported in those aged 65-80 years [4][5][6][7]. OAB appears to affect similar proportions of women and men, although some of the available evidence suggests a slightly higher prevalence in women [3][4][5]8].…”

Section: Introductionmentioning

confidence: 99%

The Prevalence of Overactive Bladder Symptoms in Women in Algeria, Egypt, Jordan and Lebanon: A Cross-Sectional Population-Based Survey

et al. 2020

View full text Add to dashboard Cite

Aims Estimate the prevalence of symptoms suggestive of overactive bladder (OAB) in women living in the Middle East to describe their demographic characteristics and explore treatment-seeking behavior. Methods Cross-sectional, population-based survey of women aged ≥ 40 years resident in Algeria, Jordan, Lebanon or Egypt. Respondents were recruited using computer-assisted telephone interview over approximately 4 months. Eligible respondents were asked to complete the OAB-V8, a validated questionnaire that explores the extent of bother from the key symptoms of OAB without clinical investigations. In addition, information regarding demographics, comorbidities and treatment behavior was collected, and respondents were stratified by age. Results A total of 2297 eligible women agreed to participate. Mean age was 54 ± 10 years; over half (59.3%) were aged 40–55 years. Overall, 53.8% of eligible women had symptoms suggestive of OAB (Jordan 58.5%; Egypt 57.5%; Algeria 49.9%; Lebanon 49.0%), with over 90% also reporting symptoms of urinary incontinence. Only 13.0% of women with symptoms suggestive of OAB were currently receiving treatment, while most (74.3%) had never been treated; these data were consistent across country and age categories. Among the untreated subgroup, almost half (48.7%) reported they were ‘not bothered by symptoms,’ while 8.4% considered OAB to be ‘part of normal aging’ and 4.7% did not know it was treatable. Conclusion A high prevalence of symptoms suggestive of OAB was observed, and the majority had symptoms of urinary incontinence. Despite the high prevalence, most women had never received treatment. Considering the potential significant impact of OAB symptoms on health, quality of life and productivity, these findings highlight an unmet medical need in the population studied. Strategies to improve treatment-seeking behavior (e.g., through education and tackling the stigma associated with OAB symptoms) may improve the diagnosis, management and health outcomes of women with OAB in the Middle East. Supplementary Information The online version contains supplementary material available at 10.1007/s12325-020-01588-4.

show abstract

Cross-Sectional Epidemiological Analysis of the Nagahama Study for Correlates of Overactive Bladder: Genetic and Environmental Considerations

Abstract: The prevalence of overactive bladder was greater in men than in women, especially among the elderly. Environmental factors rather than genetic variants more likely contribute to overactive bladder.

Cited by 22 publications

References 23 publications

Cognitive behavioral therapy for overactive bladder in women: study protocol for a randomized controlled trial

Cognitive behavioral therapy for overactive bladder in women: study protocol for a randomized controlled trial

Safety and effectiveness of mirabegron in male patients with overactive bladder with or without benign prostatic hyperplasia: A Japanese post‐marketing study

The Prevalence of Overactive Bladder Symptoms in Women in Algeria, Egypt, Jordan and Lebanon: A Cross-Sectional Population-Based Survey

Contact Info

Product

Resources

About